144
Participants
Start Date
April 30, 2025
Primary Completion Date
April 30, 2026
Study Completion Date
October 31, 2026
VE818
VE818, is an 11-strain bacterial consortium rationally designed by Vedanta Biosciences Inc., to displace enteropathogens and reduce intestinal inflammation in pregnant women
Placebo
Enteric Capsules filled with approximately 400mg of Microcrystalline Cellulose (bulking agent)
Oral Vancomycin
Oral vancomycin in capsule form will be administered three times daily for 5 days at 250mg per dose. Because oral vancomycin is a non-absorbable antibiotic, the likelihood of systemic absorption is minimal and therefore, it is not associated with the adverse events attributable to the intravenous formulation
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Matlab
Bill and Melinda Gates Foundation
OTHER
International Centre for Diarrhoeal Disease Research, Bangladesh
OTHER